Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
Eli Lilly has announced that its new obesity drug, retatrutide, is more effective than existing treatments Zepbound and Wegovy. Clinical trials showed that participants lost an average of 70 pounds over 80 weeks while using retatrutide. This development marks a significant advancement in obesity treatment options.
- ▪Eli Lilly's new drug retatrutide has shown promising results in clinical trials.
- ▪Participants in the study lost an average of 70 pounds over a period of 80 weeks.
- ▪Retatrutide is reported to be more powerful than current obesity drugs Zepbound and Wegovy.
Opening excerpt (first ~120 words) tap to expand
Health Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy May 22, 20264:44 AM ET Heard on Morning Edition By Sydney Lupkin , Steve Inskeep Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy Audio will be available later today. Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy. Sponsor Message Facebook Flipboard Email
Excerpt limited to ~120 words for fair-use compliance. The full article is at NPR — Health.
Discussion
0 commentsMore from NPR — Health
